Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $17.00.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday.

Ocular Therapeutix Stock Up 2.7 %

Shares of NASDAQ:OCUL opened at $7.34 on Friday. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -5.56 and a beta of 1.22. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a 12-month low of $4.06 and a 12-month high of $11.78. The business’s 50 day moving average is $7.78 and its 200 day moving average is $8.88.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, sell-side analysts forecast that Ocular Therapeutix will post -0.98 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Donald Notman sold 11,119 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,895 shares of company stock valued at $283,772. Insiders own 3.50% of the company’s stock.

Institutional Trading of Ocular Therapeutix

Several hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Ocular Therapeutix in the fourth quarter valued at $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Ocular Therapeutix by 48.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 218,588 shares of the biopharmaceutical company’s stock valued at $1,867,000 after buying an additional 70,904 shares during the period. Two Sigma Advisers LP raised its stake in shares of Ocular Therapeutix by 252.9% in the fourth quarter. Two Sigma Advisers LP now owns 36,700 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 26,300 shares during the period. Two Sigma Investments LP raised its stake in shares of Ocular Therapeutix by 21.9% in the fourth quarter. Two Sigma Investments LP now owns 252,939 shares of the biopharmaceutical company’s stock valued at $2,160,000 after buying an additional 45,518 shares during the period. Finally, Second Line Capital LLC raised its stake in shares of Ocular Therapeutix by 29.4% in the fourth quarter. Second Line Capital LLC now owns 340,098 shares of the biopharmaceutical company’s stock valued at $2,904,000 after buying an additional 77,288 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.